Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zhejiang Fengrun Biotech is a China-based marine bioproducts manufacturer focused on the R&D, production, and sale of glucosamine, chitosan, and related chitin-derived ingredients. Founded in 1996 in Zhejiang Province, the company positions itself as one of the larger Chinese manufacturers of chitin derivatives, with products used across pharmaceuticals, health supplements, food additives, and cosmetics. Its core commercial portfolio includes glucosamine hydrochloride, glucosamine sulfate sodium salt, glucosamine sulfate potassium salt, and N-acetyl-D-glucosamine. The company emphasizes GMP-oriented manufacturing, large-scale production capacity, and marine-sourced raw materials rather than a therapeutic drug development pipeline. Overall, it appears to be a commercial-stage specialty life science ingredients company rather than a clinical-stage biotech developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zhejiang Fengrun Biotech.